Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -44.77% is 41% above its 5-year average of -76.43%, near the high end of its 5-year range (-146.33%–-13.10%).
75.26% below its 12-month average of -25.55%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -14.32%.
RETURN ON ASSETS (ROA)
-44.77%
RETURN ON ASSETS (ROA) AVG TTM
-25.55%
RETURN ON ASSETS (ROA) AVG 3Y
-81.14%
RETURN ON ASSETS (ROA) AVG 5Y
-76.43%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-75.26%
CURRENT VS 3Y AVG
+44.82%
CURRENT VS 5Y AVG
+41.42%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-29.15%
median of 609 covered companies
CURRENT VS SECTOR MEDIAN
-53.58%
vs the sector median at left
Dogwood Therapeutics, Inc.
Market Cap
$53.15M
Return on Assets (ROA)
-44.77%
TTM Avg
-25.55%
3Y Avg
-81.14%
5Y Avg
-76.43%
Market Cap
$53.63M
Return on Assets (ROA)
-34.52%
TTM Avg
-27.74%
3Y Avg
-32.72%
5Y Avg
-28.49%
Market Cap
$52.31M
Return on Assets (ROA)
-127.67%
TTM Avg
-99.17%
3Y Avg
-76.90%
5Y Avg
-71.83%
Market Cap
$51.85M
Return on Assets (ROA)
N/A
TTM Avg
-109.69%
3Y Avg
-346.56%
5Y Avg
-277.44%
Market Cap
$51.78M
Return on Assets (ROA)
-162.93%
TTM Avg
-287.06%
3Y Avg
-300.16%
5Y Avg
-220.25%
Market Cap
$54.90M
Return on Assets (ROA)
-54.01%
TTM Avg
-81.00%
3Y Avg
-93.15%
5Y Avg
-65.68%
Market Cap
$51.33M
Return on Assets (ROA)
-97.71%
TTM Avg
-228.91%
3Y Avg
-360.64%
5Y Avg
-295.62%
Market Cap
$50.86M
Return on Assets (ROA)
-32404.78%
TTM Avg
-23.59%
3Y Avg
-11.80%
5Y Avg
-9.44%
Market Cap
$50.64M
Return on Assets (ROA)
-68.60%
TTM Avg
-124.17%
3Y Avg
-83.59%
5Y Avg
-65.75%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | $53.15M | -44.77% | -25.55% | -81.14% | -76.43% |
| ImageneBio Inc (IMA)vs › | $53.63M | -34.52% | -27.74% | -32.72% | -28.49% |
| eXoZymes, Inc. (EXOZ)vs › | $52.31M | -127.67% | -99.17% | -76.90% | -71.83% |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $51.85M | N/A | -109.69% | -346.56% | -277.44% |
| Apollomics, Inc. (APLM)vs › | $51.78M | -162.93% | -287.06% | -300.16% | -220.25% |
| Spectral AI, Inc. (MDAI)vs › | $54.90M | -54.01% | -81.00% | -93.15% | -65.68% |
| Envoy Medical, Inc. (COCH)vs › | $51.33M | -97.71% | -228.91% | -360.64% | -295.62% |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $50.86M | -32404.78% | -23.59% | -11.80% | -9.44% |
| INmune Bio, Inc. (INMB)vs › | $50.64M | -68.60% | -124.17% | -83.59% | -65.75% |
| biote Corp. (BTMD)vs › | $50.28M | 5.76% | 13.86% | 7.25% | 29.75% |
ROA
-44.8%
ROE
-52.7%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -37.99% |
| 2024-12-31 | -13.10% |
| 2023-12-31 | -127.14% |
| 2022-12-31 | -146.33% |
| 2021-12-31 | -101.16% |
| 2020-12-31 | -32.87% |
| 2019-12-31 | -783.04% |
| 2018-12-31 | -3205.57% |
